Treatment with HCQ vs standard therapy alone was linked to higher live birth rates and fewer obstetric complications among pregnant women with APS.

Greater disease activity and higher proteinuria levels were associated with a greater risk for VTE among patients with LN.

Upadacitinib and secukinumab for PsA offers comparable improvements in skin and joint symptoms, but adalimumab offers superior pain relief.

Patients with IPF and emphysema who received antifibrotic agents had similar outcomes to patients with IPF alone.

The Food and Drug Administration has approved Enoby, a biosimilar to Prolia, and Xtrenbo, a biosimilar to Xgeva.

Both medication-based and surgical weight loss interventions were linked to lower rates of obesity-related cancers in people with obesity and T2D.

Eugene Declercq, Ph.D., from Boston University in Massachusetts, and colleagues conducted a retrospective cohort study to examine the association between pregnancy-associated death or severe maternal ...

The Food and Drug Administration has granted Breakthrough Therapy designation to CD388 for seasonal influenza prevention.

The percentage of patients with a GLP-1 RA prescription before metabolic and bariatric surgery increased from 5.6% to 26.9% from 2020 to 2024.

Adults with vs without chronic back pain have a higher prevalence of noncommunicable diseases and comorbidities.

Patients with PsA who are treated with CTT are not at a greater risk for serious or opportunistic infections compared with standard therapy.

In recognition of World Arthritis Day 2025, we spoke with experts on the role of providers in enhancing care and understanding of RMDs.